Effect of itraconazole on cerivastatin pharmacokinetics

European Journal of Clinical Pharmacology

Volumn 54, Issue 11, 1999, Pages 851-855

  Kantola, T ^a   Kivisto K T ^a   Neuvonen, P J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cerivastatin; Interaction; Itraconazole

Indexed keywords

ANTIFUNGAL AGENT; CERIVASTATIN; CYPROTERONE ACETATE; DESOGESTREL; ETHINYLESTRADIOL; GESTODENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; MYCOSIS; NORMAL HUMAN; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITRACONAZOLE; MALE; PLACEBOS; PYRIDINES;

EID: 0032948727     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050566     Document Type: Article

References (22)

1. 1. Stein E, Sprecher D, Allenby KS, Tosiello RL (1997) Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: Effect of 0.2 mg daily in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol 2: 7-16
2. 2. Mück W, Ritter W, Ochmann K, Unger S, Ahr G, Wingender W, Kuhlmann J (1997) Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol Ther 35: 255-260
3. 3. Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M (1997) Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos 25: 321-331
4. 4. Bischoff H, Angerbauer R, Boberg M, Schmidt D (1997) Cerivastatin: High enzyme affinity and active metabolites contribute to its high pharmacological activity. Atherosclerosis 130 [Suppl]: S25
5. 5. Cheng H, Jusko WJ (1993) Pharmacokinetics of reversible metabolic systems. Biopharm Drug Dispos 14: 721-766
6. 6. Neuvonen PJ, Kantola T, Kivistö KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63: 332-341
7. 7. Neuvonen PJ, Jalava K-M (1996) Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 60: 54-61
8. 8. Lees RS, Lees AM (1995) Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 333: 664-665
9. 9. Horn M (1996) Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. Arch Dermatol 132: 1254
10. 10. Segaert MF, De Soete C, Vandewiele I, Verbanck J (1996) Drug-interaction-induced rhabdomyolysis. Nephrol Dial Transplant 11: 1846-1847
11. 11. Manning JA, Swanson BN, Emaus NA, Fry J (1989) A semi-automated, radioenzymatic assay for pravastatin and lovastatin in human serum. Pharm Res 6: S237
12. 12. Pentikäinen PJ, Saraheimo M, Schwartz JI, Amin RD, Schwartz MS, Brunner-Ferber F, Rogers JD (1992) Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 32: 136-140
13. 13. Allenmark S, Edebo A, Lindgren K (1990) Determination of itraconazole in serum with high-performance liquid chromatography and fluorescence detection. J Chromatogr 532: 203-206
14. 14. Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP, Vyas KP (1991) Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 290: 355-361
15. 15. Vickers S, Duncan CA, Vyas KP, Kari PH, Arison B, Prakash SR, Ramjit HG, Pitzenberger SM, Stokker G, Duggan DE (1990) In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 18: 476-483
16. 16. Lea AP, McTavish D (1997) Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 53: 828-847
17. 17. Kantola T, Kivistö KT, Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64: 58-65
18. 18. Bertz RJ, Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32: 210-258
19. IB (CYP2C9) by (±)-fluvastatin. Clin Pharmacol Ther 58: 412-417
20. 20. Haria M, McTavish D (1997) Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 53: 299-336
21. 21. Kivistö KT, Kantola T, Neuvonen PJ (1998) Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 46: 49-53
22. 22. Mück W, Ochmann K, Rohde G, Unger S, Kuhlmann J (1998) Influence of erythromycin pre-and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol 53: 469-473